ArticleJournal of mother and child2026
Immunohaematological Testing, Monitoring, and Treatment of Haemolytic Disease of the Newborn: Where are we in this Field after 25 Years?
Article in Journal of mother and child, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
contextPrevention of pregnancy-related alloimmunisation and the management of haemolytic disease of the foetus and newborn (HDFN) has significantly improved over the past decades.
aimConsidering the improved HDFN care in recent years, the goal of this 25-year analysis is to determine the epidemiological aspects of alloimmunisation during pregnancy and the presentation, diagnosis, and treatment of different types of haemolytic disease of newborns (HDN). MATERIALS AND
methodsThe retrospective study encompasses all pregnant women whose immunohaematological screening detected antibodies against any of the antigens in ABO, Rhesus, Kell, Duffy, Kidd, and/or other blood group systems or had newborns who developed HDN.
resultsOver the 25-year study period, 830/38,898 (2.1%) of immunohaematologically tested pregnant women developed alloimmunisation, while 556 (1.42%) of their newborns developed HDN. The most common form of HDN in our study was ABO HDN at 73.2% (407/556). RhD HDN was treated in 12.9% (72/556) of the newborns. Exchange transfusions (ET) were administered to 5.76% (32/556) of newborns with HDN. ET was performed on 24 (75%) with ABO HDN, and 8 (25%) with RhD HDN. The conclusion of this 25-year study is that alloimmunisation is still present, as are its consequences for the newborn. Despite better screening of pregnant women, diagnosis, and treatment of the consequences of alloimmunisation, we must know that there is no universal cure for HDN; therefore, continuous research and new guidelines in this field are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.